by The PLOS Medicine Staff
Author Archives: PLoS Medicine
by Lukasz Piwek, David A. Ellis, Sally Andrews, Adam Joinson
by Helena Nyström, Anna Nordström, Peter Nordström Background Low muscle strength has been found in late adolescence in individuals diagnosed with Parkinson disease (PD) 30 y later. This study investigated whether this lower muscle strength also may translate into increased risks of falling and fracture before the diagnosis of PD. Methods and Findings Among all Swedish citizens aged ≥50 y in 2005, two nested case–control cohorts were compiled. In cohort I, individuals diagnosed with PD during 1988–2012 (n = 24,412) were matched with up to ten controls (n = 243,363), and the risk of fall-related injuries before diagnosis of PD was evaluated.
by Matthew B. Allen, Peter P. Reese
by The PLOS Medicine Editors
by Olga Tosas Auguet, Jason R. Betley, Richard A. Stabler, Amita Patel, Avgousta Ioannou, Helene Marbach, Pasco Hearn, Anna Aryee, Simon D. Goldenberg, Jonathan A.
by Andreas Vilhelmsson, Courtney Davis, Shai Mulinari Background European Union law prohibits companies from marketing drugs off-label. In the United Kingdom—as in some other European countries, but unlike the United States—industry self-regulatory bodies are tasked with supervising compliance with marketing rules. The objectives of this study were to (1) characterize off-label promotion rulings in the UK compared to the whistleblower-initiated cases in the US and (2) shed light on the UK self-regulatory mechanism for detecting, deterring, and sanctioning off-label promotion. Methods and Findings We conducted structured reviews of rulings by the UK self-regulatory authority, the Prescription Medicines Code of Practice Authority (PMCPA), between 2003 and 2012. There were 74 off-label promotion rulings involving 43 companies and 65 drugs.
by Joseph A. Lewnard, Marina Antillón, Gregg Gonsalves, Alice M. Miller, Albert I. Ko, Virginia E.
by Jennifer Bryce, RMM Working Group
by Jennifer Bryce, Agbessi Amouzou, Cesar G. Victora, Gareth Jones, Romesh Silva, Kenneth Hill, Robert E. Black, RMM Working Group
by Monica L. Bertoia, Kenneth J. Mukamal, Leah E. Cahill, Tao Hou, David S. Ludwig, Dariush Mozaffarian, Walter C
by Darren B. Taichman, Joyce Backus, Christopher Baethge, Howard Bauchner, Peter W. de Leeuw, Jeffrey M. Drazen, John Fletcher, Frank A. Frizelle, Trish Groves, Abraham Haileamlak, Astrid James, Christine Laine, Larry Peiperl, Anja Pinborg, Peush Sahni, Sinan Wu
by Alexander C. Tsai, Mark Tomlinson, W. Scott Comulada, Mary Jane Rotheram-Borus Background Violence against women by intimate partners remains unacceptably common worldwide. The evidence base for the assumed psychological impacts of intimate partner violence (IPV) is derived primarily from studies conducted in high-income countries. A recently published systematic review identified 13 studies linking IPV to incident depression, none of which were conducted in sub-Saharan Africa
by Ingrid Chen, Siân E. Clarke, Roly Gosling, Busiku Hamainza, Gerry Killeen, Alan Magill, Wendy O’Meara, Ric N. Price, Eleanor M. Riley